Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Papillomavirus Infections 1COVID-19 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 36Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 19Papillomavirus Vaccines 16Vaccines 10Data Collection 9Blood Specimen Collection 5Vaccines, Synthetic 4artesunic acid 3artemisinin 3Engerix-B 3halofantrine 2epigallocatechin gallate 2artenimol 2Hepatitis A Vaccines 2GX-188 vaccine 2Colposcopy 2ranpirnase 1fludarabine 1Viusid 1Vitamin B 12 1VP-102 1VGX-3100 1Therapies, Investigational 1Sodium Chloride 1Pentetic Acid 1Observation 1Methods 1Measles-Mumps-Rubella Vaccine 1Interleukin-2 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Papillomavirus Infections × 2019-nCoV Vaccine mRNA-1273 × Clear all
NCT05119855 2026-02-05

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

Merck Sharp & Dohme LLC

Phase 3 Completed
165 enrolled 13 charts

COVID-19, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡